Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Calcified Tissue International|February 26, 2013
In vitro and in vivo responses to high and low doses of nitrogen-containing bisphosphonates suggest engagement of different mechanisms for inhibition of osteoclastic bone resorptionJohn E Fisher, Elizabeth Rosenberg, Arthur C Santora, et al.
Calcified Tissue International|November 27, 2012
Effects of Odanacatib on bone mineralization density distribution in thoracic spine and femora of ovariectomized adult rhesus monkeys: a quantitative backscattered electron imaging studyNadja Fratzl-Zelman, Paul Roschger, John E Fisher, et al.
Bone|March 27, 2012
Pharmacodynamic responses to combined treatment regimens with the calcium sensing receptor antagonist JTT-305/MK-5442 and alendronate in osteopenic ovariectomized ratsJohn E Fisher, Kevin Scott, Nan Wei, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 3, 2011
A rate-limiting role for Dickkopf-1 in bone formation and the remediation of bone loss in mouse and primate models of postmenopausal osteoporosis by an experimental therapeutic antibodyHelmut Glantschnig, Kevin Scott, Richard Hampton, et al.
Molecular Endocrinology (Baltimore, Md.)|October 15, 2005
Antagonist-induced, activation function-2-independent estrogen receptor alpha phosphorylationLorraine Lipfert, John E Fisher, Nan Wei, et al.
The Journal of Biological Chemistry|October 9, 2010
Generation and selection of novel fully human monoclonal antibodies that neutralize Dickkopf-1 (DKK1) inhibitory function in vitro and increase bone mass in vivoHelmut Glantschnig, Richard A Hampton, Ping Lu, et al.
Bioorganic & Medicinal Chemistry Letters|March 5, 2005
Estrogen receptor ligands. Part 10: Chromanes: old scaffolds for new SERAMsQiang Tan, Timothy A Blizzard, Jerry D Morgan, et al.
Journal of Medicinal Chemistry|October 17, 2003
Nonpeptide alphavbeta3 antagonists. 8. In vitro and in vivo evaluation of a potent alphavbeta3 antagonist for the prevention and treatment of osteoporosisJohn H Hutchinson, Wasyl Halczenko, Karen M Brashear, et al.
European Journal of Pharmacology|December 31, 2013
The preclinical efficacy, selectivity and pharmacologic profile of MK-5932, an insulin-sparing selective glucocorticoid receptor modulatorPhilip E Brandish, Kenneth Anderson, Gretchen A Baltus, et al.
Pageof 1